MEI Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEIP research report →
About the company
MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refractory follicular lymphoma and a Phase Ib multi-arm study targeting B-cell malignancies.
- CEO
- Justin J. File CPA
- IPO
- 2003
- Employees
- 28
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $20.45M
- P/E
- -0.10
- P/S
- 0.00
- P/B
- 0.11
- EV/EBITDA
- -2.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -90.81%
- ROIC
- -22.40%
- Revenue
- $0 · -100.00%
- Net Income
- $-15,945,000 · -189.69%
- EPS
- $-2.39 · -189.51%
- Op Income
- $-17,455,000
- FCF YoY
- 58.71%
- 52W High
- $9.00
- 52W Low
- $1.46
- 50D MA
- $4.55
- 200D MA
- $2.94
- Beta
- 0.22
- Avg Volume
- 1.53M
Get TickerSpark's AI analysis on MEIP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 25 | Schornstein Alexander | other | 0 |
| Aug 8, 25 | Riezman Joshua | other | 10,000 |
| Aug 5, 25 | Riezman Joshua | other | 0 |
| Jul 22, 25 | Lee Charles Benjamin | other | 0 |
| Jul 15, 25 | Wood Steven D | other | 20,000 |
| Jul 15, 25 | Reynolds Thomas C | other | 20,000 |
| Jul 15, 25 | Glover Nicholas | other | 20,000 |
| Jul 15, 25 | Flynn James P | other | 20,000 |
| Jul 15, 25 | File Justin J. | other | 20,000 |
| Jul 15, 25 | DRISCOLL FREDERICK W | other | 20,000 |
Our MEIP coverage
Recent articles, reports, and earnings notes.
No research on MEIP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MEIP report →Similar companies
Peers in the same neighborhood.